COO benefits from the strength in its business segments. Its acquisitions are likely to drive the top line.

SHEL's acquisition of TTEs 12.5% stake in the Bonga field aligns with its strategy of focusing on deepwater and offshore operations in Nigeria.

SNPS' Q2 top-line reflects strength in EDA and other segments, while efficient cost management aids earnings growth.

Wall Street is optimistic after the chip maker disclosed a strong ramp-up of its Blackwell AI platform and increasing demand from hyperscalers.

Burlington (BURL) erased premarket gains after beating earnings. HP Inc. (HPQ) blamed tariffs for higher costs in its worse-than-expected earnings report.

Revised enterprise value of US$200 million for 51% of Tembo e-LV is an increase versus the US$180 million enterprise value offered for 80% of the non affiliated shares of VivoPower

eBay stock stands out as a tariff-resilient winner that may actually benefit from a tariff-induced rise in the secondhand goods market.

I reiterate my Hold rating on TXN due to ongoing margin pressure. TXN's shift toward lower-margin personal electronics, reduced factory utilization, and higher depreciation are weighing on profitability versus historical averages. Long-term growth drivers include aggressive capital expansion, CHIPS Act support, and eventual normalization of product mix.

PITTSBURGH--(BUSINESS WIRE)--PPG's in-house tools for cradle-to-gate product carbon footprint measurement and life cycle assessment have been validated to ISO standards.

ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH. MDGL's results with its launch of MASH drug Rezdiffra demonstrate the multi-billion-dollar potential of a MASH drug, although pemvidutide will be compared to other competitors. ALT has also initiated a trial of pemvidutide in alcohol use disorder, with a trial in alcohol liver disease set to start in Q3'25.

Investors need to pay close attention to Allegro MicroSystems (ALGM) stock based on the movements in the options market lately.

GM plans to invest $888 million in the Tonawanda Propulsion plant to build next-generation V-8s with better fuel efficiency and performance.

Intuitive Surgical or Medtronic -- who leads the future of robotic surgery? Here's a comparative analysis to help you make a smart choice for 2025.

Mobile payments surge as GDOT, MQ, VYX and FOUR roll out innovations to boost volume, streamline checkout, and expand global reach.

CRM outpaces ADBE with stronger AI growth, better valuation, and steadier earnings, giving CRM the edge in cloud software stocks.

NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on May 15, 2025, disclosing that the U.S. Food and Drug Administration ("FDA") "has indicated that it is currently planning to hold an advisory committee meeting to discuss" the Company's "supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS).

NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Meta Platforms, Inc. ("Meta Platforms, Inc.") (NASDAQ:META) concerning possible violations of federal securities laws. The Wall Street Journal published an article on May 15, 2025, entitled "Meta Is Delaying the Rollout of Its Flagship AI Model.

TAMPA, Fla.--(BUSINESS WIRE)--The Baldwin Group, in collaboration with Nasdaq, Inc. (“Nasdaq”), today released its 2025 Directors & Officers (D&O) Benchmarking Report, offering one of the most comprehensive views to date of D&O insurance trends across public companies by industry and market capitalization. Now in its fourth year, the report confirms a continuing decline in premium rates and retentions—but also reveals a growing disconnect between what companies are buying and what t.

Hims & Hers Health shows strong growth in subscribers, revenue, and profitability, driven by expanding offerings and strategic partnerships, especially in weight loss and dermatology. HIMS posted stellar Q1 FY 2025: Revenue +110%, EBITDA +181%, EPS +300%. Growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Management's ambitious 2030 strategy leverages AI, new specialties, and global expansion, aiming for significant top-line and EPS growth.

Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.